Our top pick for
Magellan Health, Inc is a healthcare plans business based in the US. Magellan Health shares (MGLN) are listed on the NASDAQ and all prices are listed in US Dollars. Magellan Health employs 10,100 staff and has a trailing 12-month revenue of around USD$7.1 billion.
|52-week range||USD$30.6 - USD$95.43|
|50-day moving average||USD$93.9756|
|200-day moving average||USD$81.5818|
|Wall St. target price||USD$94|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$5.321|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Magellan Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Magellan Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Magellan Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Magellan Health shares trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Magellan Health's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.93. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Magellan Health's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Magellan Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$186.8 million.
The EBITDA is a measure of a Magellan Health's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$7.1 billion|
|Operating margin TTM||1.58%|
|Gross profit TTM||USD$227.2 million|
|Return on assets TTM||2.15%|
|Return on equity TTM||5.54%|
|Market capitalisation||USD$2.4 billion|
TTM: trailing 12 months
There are currently 787,362 Magellan Health shares held short by investors – that's known as Magellan Health's "short interest". This figure is 51.3% up from 520,568 last month.
There are a few different ways that this level of interest in shorting Magellan Health shares can be evaluated.
Magellan Health's "short interest ratio" (SIR) is the quantity of Magellan Health shares currently shorted divided by the average quantity of Magellan Health shares traded daily (recently around 690668.42105263). Magellan Health's SIR currently stands at 1.14. In other words for every 100,000 Magellan Health shares traded daily on the market, roughly 1140 shares are currently held short.
However Magellan Health's short interest can also be evaluated against the total number of Magellan Health shares, or, against the total number of tradable Magellan Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Magellan Health's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Magellan Health shares in existence, roughly 30 shares are currently held short) or 0.0397% of the tradable shares (for every 100,000 tradable Magellan Health shares, roughly 40 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Magellan Health.
Find out more about how you can short Magellan Health stock.
We're not expecting Magellan Health to pay a dividend over the next 12 months.
Over the last 12 months, Magellan Health's shares have ranged in value from as little as $30.6 up to $95.43. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Magellan Health's is 1.2465. This would suggest that Magellan Health's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Magellan Health, Inc., together with its subsidiaries, provides healthcare management services in the United States. The company operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine. It also contracts with state Medicaid agencies, and the centers for Medicare and Medicaid services to manage care for beneficiaries under Medicaid and Medicare programs, such as healthcare and long-term support services through its network of medical and behavioral health professionals, clinics, hospitals, nursing facilities, home care agencies, and ancillary service providers. The Pharmacy Management segment comprises products and solutions that provide clinical and financial management of pharmaceuticals paid under medical and pharmacy benefit programs. Further, it offers pharmacy benefit management services, such as pharmaceutical dispensing services; pharmacy benefit administration for state Medicaid and other government sponsored programs; clinical and formulary management programs; medical pharmacy management programs; and programs for the integrated management of specialty drugs that treat complex conditions. In addition, the company provides services to health plans and other managed care organizations, employers, labor unions, various military and governmental agencies, and third party administrators. Magellan Health, Inc. was incorporated in 1969 and is headquartered in Phoenix, Arizona.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.